Very Early PSA Response to Abiraterone in mCRPC Patients: A Novel Prognostic Factor Predicting Overall Survival

Background: Abiraterone Acetate (AA) is approved for the treatment of mCRPC after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicated and for treatment of mCRPC progressed during or after docetaxel-based chemotherapy regimen. The aim of this study is to evalu...

Descripción completa

Detalles Bibliográficos
Autores principales: Facchini, Gaetano, Caffo, Orazio, Ortega, Cinzia, D'Aniello, Carmine, Di Napoli, Marilena, Cecere, Sabrina C., Della Pepa, Chiara, Crispo, Anna, Maines, Francesca, Ruatta, Fiorella, Iovane, Gelsomina, Pisconti, Salvatore, Montella, Maurizio, Berretta, Massimiliano, Pignata, Sandro, Cavaliere, Carla
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2016
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4870277/
https://www.ncbi.nlm.nih.gov/pubmed/27242530
http://dx.doi.org/10.3389/fphar.2016.00123

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4870277/
https://www.ncbi.nlm.nih.gov/pubmed/27242530
http://dx.doi.org/10.3389/fphar.2016.00123

Ejemplares similares